PUBLISHER: Grand View Research | PRODUCT CODE: 2018389
PUBLISHER: Grand View Research | PRODUCT CODE: 2018389
The global cold plasma market size was estimated at USD 167.8 million in 2025 and is projected to reach USD 495.9 million by 2033, growing at a CAGR of 14.6% from 2026 to 2033. This growth is attributed to the overall development of the healthcare industry, which has increased the demand for advanced technologies to enhance patient treatment procedures and make them safe and non-invasive.
In addition, cold plasma technology enhances applications such as cancer treatment, sterilization, and wound healing, driving the market's growth significantly. Cold plasma, also known as non-equilibrium plasma, is a partially ionized gas in which the temperatures of its constituents differ significantly. It is generated by supplying energy to gases, creating reactive species useful in various applications, including medical treatments, sterilization, and food safety, without the harmful effects of high-temperature plasmas.
According to research by the University of Michigan, cold plasma is the most effective solution for removing dangerous airborne viruses. Non-thermal plasma can remove up to 99% of the virus in fractions of a second. This creates opportunities for doctors to treat patients with breathing problems using cold plasma technologies.
Increasing applications across various industries, including textiles, food safety, and medical sectors, significantly contribute to market growth. In addition, the rising demand for sustainable and efficient processing technologies, alongside innovations in food decontamination and medical treatments, further fuels this growth. Furthermore, the market is supported by advancements in atmospheric cold plasma technology, which offers eco-friendly solutions without harmful chemicals, enhancing its attractiveness to diverse industries.
The rising incidence of hospital-acquired infections (HAIs) is a critical driver of the cold plasma market, as healthcare facilities seek effective solutions for infection control and sterilization. For instance, according to the World Health Organization (WHO), HAIs affect hundreds of millions of patients worldwide each year, leading to increased morbidity, extended hospital stays, and higher healthcare costs. In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates that about 1 in 31 hospital patients has at least one HAI on any given day, contributing to approximately 99,000 deaths annually.
Rising cases of hospital-acquired infections (HAIs) are significantly driving the growth of the cold plasma market. Cold plasma technology is increasingly recognized for its effective antimicrobial properties, making it a valuable solution for infection control and sterilization in healthcare settings. As hospitals strive to reduce HAIs and enhance patient safety, the demand for innovative technologies like cold plasma continues to rise. For instance, according to the Global Report on Infection Prevention and Control (2024) by the World Health Organization (WHO), out of every 100 patients in acute-care hospitals, 7 patients in high-income countries (HICs) and 15 patients in low-income countries (LMICs) acquired at least one HAI during their hospital stay.
Global Cold Plasma Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and analyzes the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cold plasma market report based on pressure, application, and region.